BI 1015550 was granted Orphan Drug Designation by the US FDA for idiopathic pulmonary fibrosis in February this year. Credit: kalhh from Pixabay.

Boehringer Ingelheim has enrolled the first subject in the Phase III FIBRONEER-IPF clinical trial of BI 1015550 to treat idiopathic pulmonary fibrosis (IPF) patients. 

This trial is part of the FIBRONEER international programme, which comprises two Phase III studies, FIBRONEER-IPF and FIBRONEER-ILD.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

FIBRONEER-IPF is being carried out in IPF patients while FIBRONEER-ILD is for individuals with other progressive fibrosing interstitial lung diseases (ILDs). 

These double-blind, randomised, placebo-controlled trials are designed to evaluate the safety, efficacy, and tolerability of BI 1015550 over a minimum of 52 weeks in IPF and progressive fibrosing ILD patients. 

The absolute variation in forced vital capacity (FVC) from baseline at week 52 is the primary endpoint of both studies. 

The time to the first incidence of any of the following components of the composite endpoint: time to first exacerbation of acute IPF/ILD, first hospital admission for respiratory cause, or mortality during the studies is the key secondary endpoint.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Subject-reported outcomes will be evaluated as the additional secondary endpoints of the trials. 

An oral investigational therapy, BI 1015550 is an inhibitor of phosphodiesterase 4B (PDE4B).

In February this year, the therapy was granted Orphan Drug Designation by the US Food and Drug Administration (FDA) for IPF.

Boehringer Ingelheim Pulmonary Fibrosis director Dr Donald Zoz said: “As the global market leader in pulmonary fibrosis, our ambition is to move beyond slowing down disease progression and one day provide a cure for this devastating condition. 

“Enrolling the first patient in our Phase III programme is a critical step to help bring forward this next generation of treatment to those in need as quickly as possible.” 

In May this year, the company reported Phase II trial data where BI 1015550 demonstrated to reduce the rate of lung function decline in IPF patients.